1
|
Méndez-García LA, González-Chávez A, Trejo-Millán F, Navarrete-Zarco HU, Carrero-Aguirre M, Meléndez G, Chávez A, Escobedo G. Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study. Arch Med Res 2019; 50:197-206. [DOI: 10.1016/j.arcmed.2019.08.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 07/31/2019] [Accepted: 08/07/2019] [Indexed: 10/25/2022]
|
2
|
Beall RF, Schwalm JDR, Huffman MD, McCready T, Yusuf S, Attaran A. Could patents interfere with the development of a cardiovascular polypill? J Transl Med 2016; 14:242. [PMID: 27538505 PMCID: PMC4991009 DOI: 10.1186/s12967-016-0997-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2016] [Accepted: 08/02/2016] [Indexed: 12/31/2022] Open
Abstract
Background The Wellcome Trust, the World Health Organization, and cardiologists have advocated for the idea of a “polypill” containing multiple cardiovascular drugs to be co-formulated into a single pill for over a decade. Some cardiologists have asserted that the drugs commonly considered for inclusion into such a polypill are older and therefore free of patent protection. We tested this assertion. This project was requested by the World Heart Federation (WHF). Methods, data and materials Two cardiologists from the WHF provided a list of 48 cardiovascular drugs for evaluation. We designated the United States and Canada as the base jurisdictions for this patent study. We linked patent data from these countries’ national medicine patent registers to patent information in over 96 other countries using Derwent and INPADOC via Thomson Innovation. We expanded our study beyond the aforementioned data linkage through a systematic search of the World Intellectual Property Organization’s PatentScope, which was based primarily upon the drugs’ active ingredient names. Results In the United States and Canada, eight of the drugs were only available in the patent-protected, brand name formulation in one or both countries. Another 21 drugs had relevant patents, but generic equivalents were nevertheless available. Only 19 drugs (40 %) appeared entirely post-patent. Broadening the co-formulation searches globally, the overwhelming majority of drugs (40/48) were mentioned in patent applications for cardiovascular drug combinations. Conclusion The assertion that most of these cardiovascular drugs are post-patent is accurate, but only in the sense that many of the original patents on these active ingredients have expired and that generic alternatives are usually available. The landscape of patents covering novel (co-) formulations is far more complex, however. Most research and development for cardiovascular combination medicines are likely to be undertaken by companies whose original patents on the active ingredient will soon expire or have recently expired. Cardiologists looking to accelerate polypill development may consider approaching such companies to partner. Electronic supplementary material The online version of this article (doi:10.1186/s12967-016-0997-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Reed F Beall
- Population Health Program, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada. .,Faculties of Law, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada. .,Faculties of Medicine, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada.
| | - Jon-David R Schwalm
- Population Health Research Institute (PHRI), Hamilton Health Sciences, McMaster University, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada
| | - Mark D Huffman
- Feinberg School of Medicine, Northwestern University, Arthur J. Rubloff Building, 420 East Superior Street, Chicago, IL, 60611, USA
| | - Tara McCready
- Population Health Research Institute (PHRI), Hamilton Health Sciences, McMaster University, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada
| | - Salim Yusuf
- Population Health Research Institute (PHRI), Hamilton Health Sciences, McMaster University, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada
| | - Amir Attaran
- Population Health Program, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada.,Faculties of Law, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada.,Faculties of Medicine, University of Ottawa, One Stewart St, Ottawa, ON, K1N 6N5, Canada
| |
Collapse
|
4
|
González-Juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill. ACTA ACUST UNITED AC 2016; 69:547-50. [PMID: 27062678 DOI: 10.1016/j.rec.2016.02.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 02/09/2016] [Indexed: 10/22/2022]
Affiliation(s)
| | | | - José María Lobos
- Sociedad Española de Medicina de Familia y Comunitaria, Barcelona, Spain
| | - Benjamín Abarca
- Sociedad Española de Médicos Generales y de Familia, Madrid, Spain
| | | |
Collapse
|
5
|
Barrios V, Escobar C. Improving cardiovascular protection: focus on a cardiovascular polypill. Future Cardiol 2016; 12:181-96. [DOI: 10.2217/fca.15.80] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Lack of adherence may explain, at least in part, the poor cardiovascular risk factors control observed in patients with ischemic heart disease, increasing the risk of developing new events. Polypill improves medication adherence, which may actually reduce blood pressure and LDL cholesterol compared with the drugs given separately. The fixed combination of acetylsalicylic acid 100 mg + ramipril 2.5, 5, or 10 mg + either simvastatin 40 mg or atorvastatin 20 mg is the unique cardiovascular polypill that has been registered in 22 countries worldwide. The polypill-containing simvastatin has been specifically tested in a clinical trial including only patients with ischemic heart disease. The FOCUS study showed that patients treated with the polypill showed a higher adherence compared with those receiving separate medications.
Collapse
Affiliation(s)
- Vivencio Barrios
- Department of Cardiology, University Hospital Ramon y Cajal, School of Medicine. University of Alcalá, Madrid, Spain
| | - Carlos Escobar
- Cardiology Department, University Hospital La Paz, Madrid, Spain
| |
Collapse
|